{"id":89766,"date":"2026-07-24T17:42:07","date_gmt":"2026-07-24T17:42:07","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/89766\/"},"modified":"2026-07-24T17:42:07","modified_gmt":"2026-07-24T17:42:07","slug":"gsk-admits-70759-new-shares-to-london-market-gsk-sec-filing","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/89766\/","title":{"rendered":"GSK admits 70,759 new shares to London market | GSK SEC Filing"},"content":{"rendered":"<p>UNITED STATES<\/p>\n<p>SECURITIES AND EXCHANGE COMMISSION<\/p>\n<p>Washington, D.C. 20549<\/p>\n<p>\n\u00a0<\/p>\n<p>Form 6-K<\/p>\n<p>\n\u00a0<\/p>\n<p>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR<br \/>\n15d-16<\/p>\n<p>UNDER THE SECURITIES EXCHANGE ACT OF 1934<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\nFor the<br \/>\nmonth of July 2026<\/p>\n<p>\n\u00a0<\/p>\n<p>\nCommission<br \/>\nFile Number 001-15170<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>GSK plc<\/p>\n<p>\n(Translation<br \/>\nof registrant&#8217;s name into English)<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>79 New Oxford Street, London, WC1A 1DG<\/p>\n<p>\n(Address<br \/>\nof principal executive office)<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\nIndicate<br \/>\nby check mark whether the registrant files or will file annual<br \/>\nreports under cover of Form 20-F or Form 40-F.<\/p>\n<p>\n\u00a0<\/p>\n<p>\nForm<br \/>\n20-F . . . .X. . . . Form 40-F . . . . . . . .<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>Issued: 24 July 2026, London UK<\/p>\n<p>\u00a0<\/p>\n<p>Admission to trading<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>In\u00a0conformity with PRM 1.6.4R, GSK plc notifies the market<br \/>\nthat ordinary shares of 31\u00bc pence each (&#8216;Ordinary Shares&#8217;)<br \/>\nhave been admitted to trading as set out in the table below. The<br \/>\nOrdinary Shares have been admitted to trading under existing block<br \/>\nlisting admissions of Ordinary Shares in connection with the<br \/>\n&#8220;GlaxoSmithKline plc Share Save Plan 2022&#8221;.<\/p>\n<p>\u00a0<\/p>\n<p>\n1a<\/p>\n<p>\nIssuer<br \/>\nname<\/p>\n<p>\n\u00a0<\/p>\n<p>\nGSK<br \/>\nplc<\/p>\n<p>\n1b<\/p>\n<p>\nIssuer<br \/>\nLEI<\/p>\n<p>\n\u00a0<\/p>\n<p>\n5493000HZTVUYLO1D793<\/p>\n<p>\n2<\/p>\n<p>\nRegulated<br \/>\nmarket on which the securities have been admitted to<br \/>\ntrading<\/p>\n<p>\n\u00a0<\/p>\n<p>\nLondon<br \/>\nStock Exchange &#8211; Main Market<\/p>\n<p>\n3<\/p>\n<p>\nName,<br \/>\ntype and ISIN of the securities<\/p>\n<p>\nOrdinary<br \/>\nShares of 31\u00bc pence each<\/p>\n<p>\n\u00a0<\/p>\n<p>\nISIN:<br \/>\nGB00BN7SWP63<\/p>\n<p>\n\u00a0<\/p>\n<p>\n4<\/p>\n<p>\nNumber<br \/>\nof further\u00a0securities\u00a0admitted to trading covered by this<br \/>\nnotification<\/p>\n<p>\n\u00a0<\/p>\n<p>\n70,759<\/p>\n<p>\n5<\/p>\n<p>\nTotal<br \/>\nnumber of\u00a0securities\u00a0admitted to trading following<br \/>\nadmission<\/p>\n<p>\n\u00a0<\/p>\n<p>\n4,316,292,310<\/p>\n<p>\n6<\/p>\n<p>\nFungibility<\/p>\n<p>\n\u00a0<\/p>\n<p>\nFully<br \/>\nfungible with existing Ordinary Shares<\/p>\n<p>\n7<\/p>\n<p>\nDate<br \/>\nrange covered by the notification<\/p>\n<p>\n29<br \/>\nMay 2026 &#8211; 24 July 2026<\/p>\n<p>\n\u00a0<\/p>\n<p>\n8<\/p>\n<p>\nProspectus<br \/>\ninformation<\/p>\n<p>\nN\/A<\/p>\n<p>\n\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>V A Whyte<\/p>\n<p>Company Secretary<\/p>\n<p>\u00a0<\/p>\n<p>24 July 2026<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>About GSK<\/p>\n<p>GSK is a global biopharma company with a purpose to unite science,<br \/>\ntechnology, and talent to get ahead of disease together. Find out<br \/>\nmore at\u00a0www.gsk.com.<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Registered in England &amp; Wales:<\/p>\n<p>\u00a0<\/p>\n<p>\nNo.<br \/>\n3888792<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>Registered Office:<\/p>\n<p>\u00a0<\/p>\n<p>\n79<br \/>\nNew Oxford Street<\/p>\n<p>\u00a0<\/p>\n<p>\nLondon<\/p>\n<p>\u00a0<\/p>\n<p>WC1A 1DG<\/p>\n<p>\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>SIGNATURES<\/p>\n<p>\n\u00a0<\/p>\n<p>\n\u00a0<\/p>\n<p>\nPursuant<br \/>\nto the requirements of the Securities Exchange Act of 1934, the<br \/>\nregistrant has duly caused this report to be signed on its behalf<br \/>\nby the undersigned, thereunto duly authorised.<\/p>\n<p>\u00a0<\/p>\n<p>GSK plc<\/p>\n<p>\u00a0<\/p>\n<p>\n(Registrant)<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\nDate:\u00a0July<br \/>\n24, 2026<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\nBy:\/s\/\u00a0VICTORIA<br \/>\nWHYTE<\/p>\n<p>\n&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>\nVictoria\u00a0Whyte<\/p>\n<p>\u00a0<\/p>\n<p>\nAuthorised<br \/>\nSignatory for and on<\/p>\n<p>\u00a0<\/p>\n<p>\nbehalf<br \/>\nof GSK plc<\/p>\n","protected":false},"excerpt":{"rendered":"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 Form 6-K \u00a0 REPORT OF FOREIGN PRIVATE ISSUER&hellip;\n","protected":false},"author":2,"featured_media":67042,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[33672,38615,31732,20785,21214,321,24547,38614],"class_list":["post-89766","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-admission-to-trading","tag-block-listing","tag-form-6-k","tag-gsk","tag-gsk-plc","tag-london-stock-exchange","tag-ordinary-shares","tag-share-save-plan-2022"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116976192363540252","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/89766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=89766"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/89766\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/67042"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=89766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=89766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=89766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}